{
    "eid": "2-s2.0-85025467423",
    "title": "2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis",
    "cover-date": "2017-09-01",
    "subject-areas": [
        {
            "$": "Rheumatology",
            "@code": "2745"
        }
    ],
    "keywords": [
        "biologic agents",
        "clinical practice guidelines",
        "disease modifying anti-rheumatic drugs",
        "recommendations",
        "rheumatoid arthritis",
        "targeted therapy"
    ],
    "authors": [
        "Worawit Louthrenoo"
    ],
    "citedby-count": 12,
    "ref-count": 164,
    "ref-list": [
        "The AGREE II Instrument",
        "APLAR rheumatoid arthritis treatment recommendations",
        "A new system for grading recommendations in evidence based guidelines",
        "The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis",
        "2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative",
        "Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: Slight improvement over the 1987 ACR criteria",
        "Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: Comparison with 1987 ACR criteria in a very early synovitis cohort",
        "Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria",
        "Comparison of the 1987 ACR and 2010 ACR/EULAR classification criteria for rheumatoid arthritis in clinical practice: A prospective cohort study",
        "Do the 2010 ACR/EULAR or ACR 1987 classification criteria predict erosive disease in early arthritis?",
        "Significance of anti-CCP antibodies in modification of 1987 ACR classification criteria in diagnosis of rheumatoid arthritis",
        "Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial",
        "Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the best study): A randomized, controlled trial",
        "Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis",
        "Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: The impacts of remission and tumour necrosis factor blockade",
        "In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis",
        "Outcome assessments in rheumatoid arthritis",
        "Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations",
        "Comparison of three rheumatoid arthritis disease activity scores in clinical routine",
        "Active foot synovitis in patients with rheumatoid arthritis: Applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement",
        "Remission in early rheumatoid arthritis defined by 28 joint counts: Limited consequences of residual disease activity in the forefeet on outcome",
        "American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials",
        "Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association",
        "Infliximab and methotrexate in the treatment of rheumatoid arthritis",
        "The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial",
        "Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial",
        "Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial",
        "Sustained Improvement Over Two Years in Physical Function, Structural Damage, and Signs and Symptoms Among Patients With Rheumatoid Arthritis Treated With and Methotrexate",
        "Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial",
        "A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis",
        "Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial",
        "Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial",
        "Golimumab, a human antibody to tumour necrosis factor \u03b1 given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study",
        "Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: Results through 2 years of the go-forward study extension",
        "Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: Results from the GO-FORWARD study",
        "The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial",
        "Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological na\u00efve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))",
        "Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-Year results from the randomised controlled trial IMAGE",
        "Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab - Results of the dose-ranging assessment: International clinical evaluation of rituximab in rheumatoid arthritis (DANCER) trial",
        "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial",
        "Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study",
        "Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab",
        "Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year",
        "Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial",
        "Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life",
        "Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 7-year extended study",
        "Abatacept inhibits progression of structural damage in rheumatoid arthritis: Results from the long-term extension of the AIM trial",
        "Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial",
        "Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs",
        "A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.",
        "Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial",
        "Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study",
        "Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: a meta-analysis with indirect comparisons.",
        "Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis",
        "Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate",
        "The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrolment: Data from a systematic review and meta-analysis",
        "Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis",
        "Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): A systematic review and meta-analysis",
        "Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: A meta-analysis of randomized double-blind controlled studies",
        "Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study",
        "Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis",
        "Treating rheumatoid arthritis to target: Recommendations of an international task force",
        "Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs",
        "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update",
        "2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis",
        "Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis.",
        "Effects of glucocorticoids on radiological progression in rheumatoid arthritis",
        "Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: A meta-analysis",
        "Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: A network meta-analysis",
        "Are all biologics the same? Optimal treatment strategies for patients with early rheumatoid arthritis: Systematic review and indirect pairwise meta-analysis",
        "Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?",
        "Effectiveness of TNF inhibitor switch in RA: Results from the national Swedish register",
        "Outcomes of switching anti-TNF drugs in rheumatoid arthritis-a study based on observational data from the finnish register of biological treatment (ROB-FIN)",
        "Outcomes after switching from one anti-tumor necrosis factor \u03b1 agent to a second anti-tumor necrosis factor \u03b1 agent in patients with rheumatoid arthritis: Results from a Large UK National Cohort Study",
        "Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: A cohort study",
        "Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers",
        "Lack of efficacy of a third tumour necrosis factor \u03b1 antagonist after failure of a soluble receptor and a monoclonal antibody",
        "Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks",
        "Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Phramongkutklao College of Medicine",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Ramathibodi Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chiang Mai",
            "affilname": "Faculty of Medicine, Chiang Mai University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hatyai",
            "affilname": "Faculty of Medicine, Prince of Songkla University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Vajira Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "affilname": "Faculty of Medicine, Thammasat University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Rajavithi Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": null,
            "affilname": "Pha Pok Klao Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Vibhavadi Hospital",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}